ER (+) and progesterone receptor-positive (PR (+)) have been regarded as protective elements for the prognosis of breast cancer in most past research.[31,32] It is argued that hormone therapy is effective for hormone-receptor-positive (HR+) patients, which provides broader therapeutic approaches for her2 positive patients. Here, ESR1 is linked to breast cancer.